ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2007-2-72-82ssmu-3258Research ArticleРЕЗУЛЬТАТЫ ИССЛЕДОВАНИЙ МОЛОДЫХ УЧЕНЫХ И СТУДЕНТОВTHE RESULTS OF YOUNG SCIENTISTS’ AND STUDENTS’ INVESTIGATIONSБиологические функции комплементаBiological functions of complementОдинцовЮ. Н.OdintsovYu. N.noemail@neicon.ruПерельмутерВ. М.PerelmuterV. M.Сибирский государственный медицинский университет, г. ТомскRussian FederationСибирский государственный медицинский университетRussian Federation200730062007627282Copyright © Одинцов Ю.Н., Перельмутер В.М., 20072007Одинцов Ю.Н., Перельмутер В.М.Odintsov Y.N., Perelmuter V.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/3258

Комплемент является одним из важнейших факторов резистентности организма. Система комплемента может принимать участие в различных эффекторных механизмах, прежде всего в лизисе (комплементарный киллинг) и опсонизации микроорганизмов. В переключении литической функции комплемента на опсоническую могут принимать участие макрофаги. Функции комплемента при бактериозах зависят от особенностей патогенеза инфекционного заболевания.

One of the true basic resistance factors is complement. Main functions of it consist in bacterial lysis, bacterial opsonisation for phagocytosis. Alteration of lytic function for opsonic function depends upon macrophages. Complement functions at bacteriosis depend on phathogenesis features in infectious disease.

комплементбактериолизопсонизацияинфекционный процессcomplementbakteriolysisopsonisationinfectious processReferencesОдинцов Ю.Н., Перельмутер В.М., Климентьева Т.К. Тафтсин: роль в развитии негранулематозных и гранулематозных бактериозов // Бюл. сиб. медицины. 2002. Т. 1. № 3. С. 98-102.Одинцов Ю.Н., Перельмутер В.М., Климентьева Т.К. Тафтсин: роль в развитии негранулематозных и гранулематозных бактериозов // Бюл. сиб. медицины. 2002. Т. 1. № 3. С. 98-102.Перельмутер В.М., Одинцов Ю.Н. Основная функция иммуноглобулинов класса M (IgM) - регуляция проницаемости гематотканевого барьера для бактерий и их антигенов // Бюл. сиб. медицины. 2005. Т. 4. № 3. С. 38-42.Перельмутер В.М., Одинцов Ю.Н. Основная функция иммуноглобулинов класса M (IgM) - регуляция проницаемости гематотканевого барьера для бактерий и их антигенов // Бюл. сиб. медицины. 2005. Т. 4. № 3. С. 38-42.Ройт А. Основы иммунологии. Пер. с англ. М.: Мир, 1991. 328 с.Ройт А. Основы иммунологии. Пер. с англ. М.: Мир, 1991. 328 с.Ройт А., Бростофф Дж., Мейл Д. Иммунология. Пер. с англ. М.: Мир, 2000. 581 с.Ройт А., Бростофф Дж., Мейл Д. Иммунология. Пер. с англ. М.: Мир, 2000. 581 с.Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. М.: Медицина, 2000. 432 с.Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. М.: Медицина, 2000. 432 с.Ярилин А.А. Основы иммунологии. М.: Медицина, 1999. 607 с.Ярилин А.А. Основы иммунологии. М.: Медицина, 1999. 607 с.Alban S., Classen B., Brunner G., Blaschek W. Differentiation between the complement modulating effects of an arabinogalactan-protein from Echinacea purpurea and heparin // Planta Med. 2002. V. 68 (12). P. 1118-1124.Alban S., Classen B., Brunner G., Blaschek W. Differentiation between the complement modulating effects of an arabinogalactan-protein from Echinacea purpurea and heparin // Planta Med. 2002. V. 68 (12). P. 1118-1124.Ambrosio A.R., De Messias-Reason I.J. Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation. An antibody-independent defence mechanism // Parasite Immunol. 2005. V. 27. P. 333-340.Ambrosio A.R., De Messias-Reason I.J. Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation. An antibody-independent defence mechanism // Parasite Immunol. 2005. V. 27. P. 333-340.Andersson J., Larsson R., Richter R. et al. Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surfacebound factor H inhibits complement activation // Biomaterials. 2001. V. 22. P. 2435-2443.Andersson J., Larsson R., Richter R. et al. Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surfacebound factor H inhibits complement activation // Biomaterials. 2001. V. 22. P. 2435-2443.Bohana-Kashtan O., Ziporen L., Donin N. et al. Cell signals transduced by complement // Mol. Immunol. 2004. V. 41. P. 583-597.Bohana-Kashtan O., Ziporen L., Donin N. et al. Cell signals transduced by complement // Mol. Immunol. 2004. V. 41. P. 583-597.Bohlson S.S., Strasser J.A., Bower J.J., Schorey J.S. Role of complement in Mycobacterium avium pathogenesis: in vivo and in vitro analyses of the host response to infection in the absence of complement component C3 // Infect. Immunol. 2001. V. 69. P. 7729- 7735.Bohlson S.S., Strasser J.A., Bower J.J., Schorey J.S. Role of complement in Mycobacterium avium pathogenesis: in vivo and in vitro analyses of the host response to infection in the absence of complement component C3 // Infect. Immunol. 2001. V. 69. P. 7729- 7735.Brown J.S., Hussell T., Gilliland S.M. et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice // Proc. Natl. Acad. Sci. USA. 2002. V. 99. P. 16969-16974.Brown J.S., Hussell T., Gilliland S.M. et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice // Proc. Natl. Acad. Sci. USA. 2002. V. 99. P. 16969-16974.Caragine T.A., Okada N., Frey A.B., Tomlinson S. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer // Cancer Res. 2002. V. 62. P. 1110-1115.Caragine T.A., Okada N., Frey A.B., Tomlinson S. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer // Cancer Res. 2002. V. 62. P. 1110-1115.Celik I., Stover C., Botto M. et al. Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis // Infect. Immun. 2001. V. 69. P. 7304-7309.Celik I., Stover C., Botto M. et al. Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis // Infect. Immun. 2001. V. 69. P. 7304-7309.Donin N., Jurianz K., Ziporen L. et al. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid // Clin. Exp. Immunol. 2003. V. 131. P. 254-263.Donin N., Jurianz K., Ziporen L. et al. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid // Clin. Exp. Immunol. 2003. V. 131. P. 254-263.Fernie-King B.A., Seilly D.J., Willers Ch. et al. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes // Immunology. 2001. V. 103. Issue 3. P. 390-408.Fernie-King B.A., Seilly D.J., Willers Ch. et al. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes // Immunology. 2001. V. 103. Issue 3. P. 390-408.Frumeaux-Bacchi V., Dragon-Durey M.A., Blouin J. et al. Investigation of the complement system in clinical practice // Ann. Med. Interne (Paris). 2003. V. 154. P. 529-540.Frumeaux-Bacchi V., Dragon-Durey M.A., Blouin J. et al. Investigation of the complement system in clinical practice // Ann. Med. Interne (Paris). 2003. V. 154. P. 529-540.Imai M., Ohta R., Okada N., Tomlinson S. Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma // Int. J. Cancer. 2004. V. 110. P. 875- 881.Imai M., Ohta R., Okada N., Tomlinson S. Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma // Int. J. Cancer. 2004. V. 110. P. 875- 881.Jiang H., Wagner E., Zhang H., Frank M.M. Complement 1 inhibitor is a regulator of the alternative complement pathway // J. Exp. Med. 2001. V. 194. № 11. P. 1609-1616.Jiang H., Wagner E., Zhang H., Frank M.M. Complement 1 inhibitor is a regulator of the alternative complement pathway // J. Exp. Med. 2001. V. 194. № 11. P. 1609-1616.Langeggen H., Berge K.E., Johnson E., Hetland G. Human umbilical vein endothelial cells express complement receptor 1 (CD35) and complement receptor 4 (CD11c/CD18) in vitro // Inflammation. 2002. V. 26. № 3. P. 103 - 110.Langeggen H., Berge K.E., Johnson E., Hetland G. Human umbilical vein endothelial cells express complement receptor 1 (CD35) and complement receptor 4 (CD11c/CD18) in vitro // Inflammation. 2002. V. 26. № 3. P. 103 - 110.Laufer J., Katz Y., Passwell J.H. Extrahepatic synthesis of complement proteins in inflammation // Mol. Immunol. 2001. V. 38. P. 221 -229.Laufer J., Katz Y., Passwell J.H. Extrahepatic synthesis of complement proteins in inflammation // Mol. Immunol. 2001. V. 38. P. 221 -229.Leslie R.G.Q., Nielsen C.H. The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes // Immunology. 2004. V. 111. Issue 1. P. 86-98.Leslie R.G.Q., Nielsen C.H. The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes // Immunology. 2004. V. 111. Issue 1. P. 86-98.Lukas T.J., Munoz H., Erickson B.W. Inhibition of C1-mediated immune hemolysis by monomeric and dimeric peptides from the second constant domain of human immunoglobulin G // J. Immunology. 1981. V. 127. № 6. P. 2555-2560.Lukas T.J., Munoz H., Erickson B.W. Inhibition of C1-mediated immune hemolysis by monomeric and dimeric peptides from the second constant domain of human immunoglobulin G // J. Immunology. 1981. V. 127. № 6. P. 2555-2560.Nauta A.J., Daha M.R., Tijsma O. et al. The membrane attack complex of complement induces caspase activation and apoptosis // Europ. J. of Immun. 2002. V. 32. Issue 3. P. 783-792.Nauta A.J., Daha M.R., Tijsma O. et al. The membrane attack complex of complement induces caspase activation and apoptosis // Europ. J. of Immun. 2002. V. 32. Issue 3. P. 783-792.Nielsen C.H., Marquart H.V., Prodinger W.M., Leslie R.G. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes // Immunol. 2001. V. 104. P. 418-422.Nielsen C.H., Marquart H.V., Prodinger W.M., Leslie R.G. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes // Immunol. 2001. V. 104. P. 418-422.Nielsen C.H., Pedersen M.L., Marquart H.V. et al. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells // Eur. J. Immunol. 2002. V. 32. P. 1359-1367.Nielsen C.H., Pedersen M.L., Marquart H.V. et al. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells // Eur. J. Immunol. 2002. V. 32. P. 1359-1367.Ren B., McCrory M.A., Pass C. et al. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptormediated protection // J. Immunol. 2004. V. 173. P. 7506-7512.Ren B., McCrory M.A., Pass C. et al. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptormediated protection // J. Immunol. 2004. V. 173. P. 7506-7512.Roos A., Ramwadhdoebe T.H., Nauta A.J. et al. Therapeutic inhibition of the early phase of complement activation // Immunobiology. 2002. V. 205. P. 595-609.Roos A., Ramwadhdoebe T.H., Nauta A.J. et al. Therapeutic inhibition of the early phase of complement activation // Immunobiology. 2002. V. 205. P. 595-609.Roos A., Bouwman L.H., Munoz J. et al. Functional characterization of the lectin pathway of complement in human serum // Mol. Immunol. 2003. V. 39. P. 655-668.Roos A., Bouwman L.H., Munoz J. et al. Functional characterization of the lectin pathway of complement in human serum // Mol. Immunol. 2003. V. 39. P. 655-668.Song H., He C., Knaak C. et al. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation// J. Clin. Invest. 2003. V. 111. P. 1875-1885.Song H., He C., Knaak C. et al. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation// J. Clin. Invest. 2003. V. 111. P. 1875-1885.Thiel S., Petersen S.V., Vorup-Jensen T. et al. Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein MAp19// J. Immunol. 2000. V. 165. P. 878-887.Thiel S., Petersen S.V., Vorup-Jensen T. et al. Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein MAp19// J. Immunol. 2000. V. 165. P. 878-887.Windbichler M., Echtenacher B., Hehlgans T. et al. Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis // Infection and Immunity. 2004. V. 72. № 9. P. 5247-5252.Windbichler M., Echtenacher B., Hehlgans T. et al. Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis // Infection and Immunity. 2004. V. 72. № 9. P. 5247-5252.

The authors declare that there are no conflicts of interest present.